Caris Life Sciences (CAI) Asset Utilization Ratio (2025 - 2026)

Caris Life Sciences (CAI) posted quarterly Asset Utilization Ratio of 0.79 for Q1 2026, up 3.05% quarter-over-quarter from 0.77 in Q4 2025.

Analysis

Caris Life Sciences (CAI) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Caris Life Sciences' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.79 for Q1 2026.

In Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.79; the TTM figure through Mar 2026 stood at 0.79 (changed N/A YoY), while the FY2025 annual figure was 1.11, changed N/A from the prior year.
Asset Utilization Ratio for Q1 2026 stood at 0.79, up from 0.77 in the prior quarter.
The five-year high for Asset Utilization Ratio was 0.79 in Q1 2026, with the low at 0.67 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.38
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.20
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.69
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	0.90
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.13
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.54
10	Caris Life Sciences	7.08 Bn	6.28 Bn	182.38 Mn	0.83

Historic Data

Download Data